Here are 1-3 brief analogies for Lakewood-Amedex Biotherapeutics (LABT):

1. Think of LABT as an early-stage Gilead Sciences, but focused exclusively on developing new classes of drugs to combat antibiotic-resistant superbugs.

2. Imagine LABT as a biotech aiming to be the Moderna for antibiotic-resistant infections, developing innovative treatments for a major global health crisis.

• Nu-3 (Bisphosphocin®): A broad-spectrum antibacterial agent under development for the topical treatment of mildly infected diabetic foot ulcers (iDFU).

Lakewood-Amedex Biotherapeutics (LABT) is currently a biotechnology company in the clinical development stage. Its lead product candidate, Bisphosphocin® (anti-bacterial) Nu-3, is undergoing human clinical trials, with plans for Phase 2a and Phase 2b studies. The company explicitly states that the "Advancement of any of our product candidates to the commercialization stage is completely dependent on the outcome of clinical studies that are reviewed and approved by the FDA or other comparable regulatory authorities."

Therefore, Lakewood-Amedex Biotherapeutics does not currently have any commercialized products, and as a result, does not have major customers (either other companies or individual consumers) at this time. Its operations are focused on research, development, and clinical trials for future market entry.

Kelvin Cooper, PhD, Chief Executive Officer

Dr. Kelvin Cooper is a seasoned pharmaceutical scientist and executive with over 45 years of experience in drug discovery and development across various therapeutic areas, including infectious disease, cancer, respiratory, immunology, and inflammation. Before joining Lakewood-Amedex, he held multiple leadership roles at Pfizer from 1981 to 2011, including Senior Vice President for Portfolio Development in their Established Pharmaceutical Sciences Business Unit and Senior Vice President of Worldwide Pharmaceutical Sciences. He also served as Executive Director of drug development and Director of Drug Discovery in various therapeutic areas. Dr. Cooper earned his Ph.D. in Organic Chemistry from the University of Nottingham and has authored 49 publications and holds 34 patents. He was appointed CEO of Lakewood-Amedex Inc. in February 2025.

Peter F. Ceccacci, Chief Financial Officer

Mr. Peter F. Ceccacci joined Lakewood-Amedex in 2009, bringing extensive financial management leadership expertise. He has an extensive career in public accounting, with nearly 20 years as a Partner at several firms. He also served as the Chief Financial Officer of a technology company, identified as Genius Central Systems, Inc. and possesses over 15 years of experience in both the life sciences and technology sectors. Mr. Ceccacci is an accomplished senior executive with comprehensive experience in accounting, finance, information systems, strategy, compliance, and management. He earned a Bachelor of Science degree in Accounting from Susquehanna University. He has been Chief Financial Officer & VP-Administration at Lakewood-Amedex Biotherapeutics, Inc. since 2025.

Thomas Balzer, MD, PhD, Chief Medical Officer

Dr. Thomas Balzer is an accomplished international healthcare professional with extensive experience in Clinical Drug Development and Medical Affairs. Most recently, he served as Head of Clinical Development at Thrive Detect, an Exact Sciences Company, where he led the development of a multi-cancer detection liquid biopsy assay. Prior to that, Dr. Balzer worked for over 25 years at Bayer HealthCare in various positions, including Vice President and Global Head of Medical Affairs & Clinical Development Radiology. During his tenure at Bayer, he built, developed, and managed global teams and successfully completed four global clinical development programs/NDAs, along with several additional indication expansions. Dr. Balzer is board-certified in Internal Medicine in Germany and holds a Ph.D. from the Free University in Berlin for his work in neuro-endocrine pharmacology. He has been Chief Medical Officer & SVP-Clinical Development at Lakewood-Amedex Biotherapeutics, Inc. since 2023.

Key Risks to Lakewood-Amedex Biotherapeutics (LABT)

• Clinical Trial Failure and Regulatory Approval Risk: As a clinical-stage biotechnology company, Lakewood-Amedex Biotherapeutics' viability is entirely dependent on the successful outcome of its ongoing and future clinical trials for its lead product, Nu-3, and subsequent regulatory approval. The company is currently planning Phase 2a and Phase 2b studies for Nu-3, following exploratory human clinical trials for the topical treatment of mildly infected diabetic foot ulcers (iDFU). Failure to demonstrate safety and efficacy in these trials, or to secure approval from regulatory bodies like the FDA, would prevent the commercialization of Nu-3 and significantly impair the company's prospects.
• Reliance on a Single Lead Product (Nu-3) Risk: The company's pipeline beyond Nu-3 consists of early-stage compounds that are still being characterized to identify suitable clinical indications. This indicates a significant concentration of the company's value and future prospects on the success of Nu-3. Should Nu-3 fail in clinical trials or face unforeseen challenges during regulatory review or commercialization, the company's ability to generate revenue and sustain operations would be severely impacted, as other product candidates are much further from reaching commercialization.
• Funding and Commercialization Risk: Lakewood-Amedex Biotherapeutics currently operates with no revenue and has reported operating losses. The company relies on financing, such as private placements, to fund its operations and advance its product candidates through costly clinical development. Even if Nu-3 successfully completes clinical trials and gains regulatory approval, the company will face substantial challenges and expenses related to manufacturing, marketing, sales, and distribution to achieve market penetration and compete with existing and emerging therapies in the antimicrobial market. A failure to secure adequate funding or successfully navigate the complex commercialization landscape could impede its ability to bring products to market and achieve profitability.

Lakewood-Amedex Biotherapeutics' lead product, Bisphosphocin® (anti-bacterial) Nu-3, targets the topical treatment of mildly infected diabetic foot ulcers (iDFU).

The global addressable market for diabetic foot ulcer treatment was valued at approximately USD 7 billion in 2024 and is projected to grow to USD 12.8 billion by 2034, exhibiting a Compound Annual Growth Rate (CAGR) of 6.3% between 2025 and 2034. For the U.S. region specifically, the diabetic foot ulcer treatment market generated approximately USD 2.5 billion in revenue in 2024 and is anticipated to grow at a CAGR of 6.4% from 2025 to 2034. While specific market size data for "mildly infected" diabetic foot ulcers with a distinct monetary value is not readily available, mildly infected cases represent a significant segment within the broader diabetic foot ulcer market.

Here are 3-5 expected drivers of future revenue growth for Lakewood-Amedex Biotherapeutics (LABT) over the next 2-3 years:

1. Successful Advancement of Nu-3 through Phase 2 Clinical Trials: The successful completion of planned Phase 2a and placebo-controlled Phase 2b studies for Nu-3, targeting mildly infected diabetic foot ulcers (iDFU), is expected to be a significant driver. Positive results from these trials would validate the efficacy and safety of Nu-3, substantially increasing the asset's value and potentially leading to significant funding rounds, equity investments, or partnership opportunities that could generate revenue through upfront payments or milestones within the 2-3 year timeframe.
2. Formation of Strategic Partnerships and Licensing Agreements for Nu-3: As Nu-3 progresses through clinical development, securing strategic partnerships or licensing agreements with larger pharmaceutical companies will be crucial for funding subsequent Phase 3 trials and eventual commercialization. Such agreements typically involve upfront payments, milestone payments tied to development progress, and potential equity investments, all of which would contribute to revenue growth over the next 2-3 years.
3. Progression and Characterization of Early-Stage Pipeline Compounds: The company is also advancing early-stage pipeline compounds, focusing on further characterizing them to identify the best clinical indications for non-clinical and clinical evaluation. Successful progression of these compounds into preclinical or early clinical stages could enhance the company's overall intellectual property and asset portfolio, potentially attracting additional funding, grants, or early-stage partnership revenue within the specified timeframe.

Share Issuance

• Lakewood-Amedex Biotherapeutics filed a prospectus (424B4) in April 2026 to register the resale of up to 4,689,177 shares of common stock by existing stockholders, from which the company will not receive proceeds.
• The company has a binding private placement agreement to sell 937,500 Series C Preferred Shares, generating aggregate gross proceeds of $7,500,000, which are convertible into Common Stock.
• In April 2026, newly appointed board member Joseph Tucker was granted 33,784 warrants to purchase common stock at $10.00 per share, vesting in tranches between October 2026 and April 2028, and will receive $6,000 per quarter in common stock as compensation.

Inbound Investments

• Lakewood-Amedex Biotherapeutics has a binding private placement for 937,500 Series C Preferred Shares, which is expected to bring in gross proceeds of $7,500,000.

Capital Expenditures

• The company plans to conduct an initial Phase 2a safety and dose response study for its lead product, Nu-3, for the topical treatment of mildly infected diabetic foot ulcers.
• Following the Phase 2a study, a placebo-controlled Phase 2b dose comparative study for Nu-3 is planned to identify the optimal dose for Phase 3 trials and eventual commercialization.
• Capital is also being allocated to advance early-stage pipeline compounds and further characterize them for non-clinical and clinical evaluation.